Comment to: Extensive analytical evaluation of the performances of the new DiaSys PCT assay and comparison with Elecsys B·R·A·H·M·S PCT test on Roche Cobas and B·R·A·H·M·S PCT-sensitive Kryptor

Letter

Author: Masetto, Thomas ; Grimmler, Matthias

06 Oct 2023·Journal of proteome research

Immunoaffinity LC-MS/MS Quantification of the Sepsis Biomarker Procalcitonin Using Magnetic- and Polystyrene-Bead Immobilized Polyclonal Antibodies.

Article

Author: Reuschel, Thomas ; Bindila, Laura ; Tölke, Sebastian-Alexander ; Schneider, Klaus ; Masetto, Thomas ; Grimmler, Matthias

Procalcitonin (PCT) is a biomarker for bacterial sepsis, and accurate quantification of PCT is critical for sepsis diagnosis and treatment. Immunological PCT quantification methods are routinely used in clinical laboratories, yet there is a need for harmonization of PCT quantification protocols. An orthogonal method to clinical immunological assays, such as LC-MS/MS, is required. In this study, a highly sensitive and robust immunoaffinity LC-MRM quantitative method for detecting procalcitonin in human serum has been developed. An initial comparison of immunocapture of PCT with a polyclonal anti-PCT antibody immobilized on polystyrene nanoparticles (Latex) and magnetic beads demonstrated superior performance with magnetic beads. Three tryptic PCT peptides from the N- and C-terminal regions of PCT were selected for LC-MS/MS quantification. For PCT quantification, an LLOQ of 0.25 ng/mL of PCT in human serum was achieved using a sample volume of 1 mL. The method's trueness and precision consistently lie within the 15% margin. The parallel measurement of three PCT peptides may allow future differentiation of intact PCT vs other PCT forms originating from potential degradation, processing, or polymorphisms. An established and validated LC-MRM-based quantification of PCT will be relevant as an orthogonal method for harmonization and standardization of clinical assays for PCT.

27 Sep 2023·Clinical Chemistry

A-072 An All-Purpose Particle Enhanced Immunoturbidimetric Assay for the Comparable, Instrument-Independent Monitoring of Procalcitonin in the Management of Sepsis

Author: Grimmler, M

AbstractIntroductionSepsis is a life-threatening organ dysfunction caused by a dysregulated host immune response to infection. It is a global health concern and a leading cause of death worldwide, affecting an estimate of 48.9 million people every year. Procalcitonin (PCT) revealed to be an indispensable parameter for the management of sepsis. However, recent analysis of EQA survey results suggested crucial deviations of PCT measurements in Germany and studies by the IFCC Working Group on standardization of PCT stated the need for a higher-order reference measurement procedure.Here we present the evaluation of the all-purpose particle enhanced immunoturbidimetric assay (PETIA) of DiaSys, which can be easily applied to every high-throughput clinical chemistry analyzer. The high diversity of applications and datasets match current diagnostic and regulative needs (IVDR). Procalcitonin FS enables the equivalent and instrument-independent monitoring of PCT in the management of sepsis.MethodologyEvaluation of Procalcitonin FS was performed on seven clinical chemistry analyzer platforms (Jeol BioMajesty® JCA-BM6010/C, DiaSys respons®920 and respons®940, Roche cobas c501, Abbott Architect c8000 and Alinity c, Beckman Olympus AU680). Measurements were performed according to Clinical and Laboratory Standards Institute (CLSI) protocols.ResultsThe onboard stability reaches 8 weeks (with chimney) on BioMajesty® JCA-BM6010/C, 20 days on respons®920 and respons®940, 21 weeks on cobas c501, 9 weeks on Architect, 12 weeks on Olympus AU680 and 13 weeks on Alinity c. The calibration stability is 4 weeks (with chimney) on BioMajesty® JCA-BM6010/C, 2 weeks (with chimney) on respons®920 and respons®940, 21 weeks on cobas c501, 3 weeks on Architect, 5 weeks on Olympus AU680 and 10 weeks on Alinity c. The intra-assay precision (CV%) ranges from ≤4.57% on respons®920 up to ≤7.19% on respons®940. The Total Precision (CV%) ranges from ≤3.99% on cobas c501 up to ≤9.62% on Olympus AU680. LOB ranges from 0.07 ng/mL on BioMajesty® JCA-BM6010/C up to 0.130 ng/mL on Olympus AU680. LOQ ranges from 0.20 ng/mL on Architect up to 0.277 ng/mL on Olympus AU680. The reagent displayed a linear recovery up to 50 ng/mL and no prozone effect was detected up to 1000 ng/mL on all seven analyzers. The Passing & Bablok regression vs the reference test showed an excellent comparability/alignment between the methods (slope ≤1.11, intercept ≤0.156 ng/mL, R ≥ 0.986).ConclusionEvaluation work proves that DiaSys PETIA reagent Procalcitonin FS shows excellent performance on all seven clinical chemistry analyzers. In addition, the high comparability between the seven analyzers enables the reliable and instrument-independent monitoring of PCT in the management of sepsis, and thus offering a solution to the current landscape of deviating PCT measurement results.

News (Medical) associated with DiaSys Diagnostic Systems GmbH

29 Mar 2023

·www.businesswire.com

Global Physician Office In Vitro Diagnostic (IVD) Test Markets, 2022-2023 & 2027 - Focus on Reagents, Test Kits, Standards and Controls, and Instruments - ResearchAndMarkets.com

DUBLIN--( BUSINESS WIRE )--The "Physician Office In Vitro Diagnostic (IVD) Test Markets" report has been added to ResearchAndMarkets.com's offering. This report analyzes trends in global demand for in vitro diagnostic (IVD) products used in physicians' office laboratories. Specific products consist of reagents, test kits, standards and controls, and instruments and systems based on immunoassay, clinical chemistry, hematology, molecular, microbiology, and coagulation technologies. Physicians' office laboratories are defined as point-of-care (POC) testing sites within traditional practices or urgent care centers staffed by one or more physicians. Most of these laboratories implement IVD procedures through one or more portable desktop instruments that yield rapid diagnostic results. Information and data appearing in this report include: Macroeconomic, demographic, epidemiological, and healthcare indicators that influence product demand patterns and growth opportunities Projected global product demand by type and technology for the years 2022 through 2027 The projected value of regional and selected national markets for physicians' office laboratory IVD products in each of the forecast years (2022 through 2027). The report also includes profiles of the major producers of physicians' office laboratory IVD products. Report coverage extends to worldwide markets, but focuses on the United States and other developed countries. The majority of physicians' practices in the developing world are located in hospitals and outpatient clinics and do not engage actively in patient testing. In addition, the report profiles key companies in the market, including: Abbott Laboratories Abingdon Health ACON Laboratories, Inc. ArcDia International Oy Ltd. Axis-Shield Diagnostics Ltd. Becton Dickinson and Company (BD) binx health, inc. Bio-Rad Laboratories, Inc. Biocartis NV Biomerica, Inc Key Topics Covered: Chapter 1: Introduction Scope & Report Coverage Methodology Sources of Information Chapter 2: Executive Summary Physicians' Office Laboratories: Market Overview Product Demand Patterns Geographical Markets Size and Growth of the Market Chapter 3: Market Environment Overview Global Economic Outlook Gross Domestic Product Per Capita Gross Domestic Product Population Age Distribution Population 50 Years & Older Population 65 Years & Older Global Healthcare Trends Medical Conditions Health Expenditures Hospital Beds Physicians Patient Activity Acute Care Hospital Admissions Surgical Procedures Physicians' Consultations IVD Tests Traditional Physicians' Offices Urgent Care Centers Physicians' Office Laboratories Chapter 4: Physicians' Office Laboratory (Pol) IVD Products Overview IVD Industry Trends IVD Technologies Immunoassays Clinical Chemistry Molecular IVD Technology Microbiology Hematology Coagulation Histology/Cytology Blood Grouping Other IVD Technologies Industry Regulations Point-Of-Care (Poc) Testing Market Physicians' Office Poc Testing: Market Overview Pol Testing Applications Infectious Disease Pol Tests Covid-19 Pol Tests Other Infectious Disease Pol Tests Colon Cancer Pol Tests Glucose Pol Tests Drugs of Abuse Pol Tests Blood Gas & Electrolyte Pol Tests Coagulation Pol Tests Cardiac Marker Pol Tests Hematology Pol Tests Hba1C Pol Tests Cholesterol Pol Tests Pregnancy/Infertility Pol Tests Cancer Marker Pol Tests Urinalysis Pol Tests Other Pol Tests Pol IVD Product Sales by Type Chapter 5: Geographical Markets Overview United States Canada Mexico Germany France United Kingdom Italy Spain Other Western Europe China India Japan South Korea Australia Other Asia/Pacific Central & South America Eastern Europe Africa/Mideast Chapter 6: Company Profiles Abbott Laboratories Abingdon Health Acon Laboratories, Inc. Arcdia International Oy Ltd. Axis-Shield Diagnostics Ltd. Becton Dickinson and Company (Bd) Binx Health, Inc. Bio-Rad Laboratories, Inc. Biocartis Nv Biomerica, Inc. Biomerieux S.A. Boule Diagnostics Ab Cardinal Health, Inc. Carolina Liquid Chemistries Corporation Chembio Diagnostics, Inc. Danaher Corporation Diasorin S.P.A. Diasys Diagnostic Systems GmbH Diazyme Laboratories, Inc. Ekf Diagnostics Holdings plc Exact Sciences Corporation Genedrive plc Horiba Ltd. Immunostics, Inc. Medmira, Inc. Meridian Bioscience, Inc. Orasure Technologies Pts Diagnostics Quantumdx Group Ltd. Quidelortho Corporation Roche Siemens Healthcare GmbH (Siemens Healthineers) Stago Group Sysmex Corporation Thermo Fisher Scientific, Inc. Trinity Biotech plc Werfen For more information about this report visit https://www.researchandmarkets.com/r/uxce56 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Diagnostic Reagents

09 Sep 2022

·www.prnewswire.com

Myoglobin Market to record USD 99.2 Mn growth -- Driven by usage of myoglobin as a biomarker for the diagnosis of ACS and muscle injuries

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- The " Myoglobin Market by Type and Geography - Forecast and Analysis 2022-2026" report has been added to Technavio's offering. The report expects the market size to grow by USD 99.2 million between 2021 and 2026, expanding at a CAGR of 4.1% during the forecast period. The report considers various aspects such as the consumer base, adoption rate, average selling price, revenue generated by vendors, and various other factors to estimate the market size. Download Sample PDF Report Attractive Opportunities in Myoglobin Market by Type and Geography - Forecast and Analysis 2022-2026 The global myoglobin market is fragmented. The market is moderately competitive and has the presence of several prominent vendors. Prominent vendors have established a sizeable market presence. The competition in the market will become more intense with the growing demand for myoglobin assays from rapid response laboratories and other healthcare facilities for emergency diagnostic patient management. Vendors need to continuously innovate their offerings and build capabilities with less service differentiation. This enables vendors to compete with larger players more effectively, intensifying competition in the market. The increasing regulatory standards and high capital requirements for setting up new production facilities ensure that the threat of emerging players in the market is low. Thus, the global myoglobin market is expected to witness moderate competition during the forecast period. The report identifies Abbott Laboratories, BBI Solutions, Bio Rad Laboratories Inc., bioMerieux SA, Boditech Med Inc., Danaher Corp., DiaSys Diagnostic Systems GmbH, F. Hoffmann La Roche Ltd., General Atomics, HORIBA Ltd., Merck KGaA, OriGene Technologies Inc., Ortho-Clinical Diagnostics Inc., PerkinElmer Inc., Randox Laboratories Ltd., Scripps Laboratories Inc., Siemens Healthineers AG, Thermo Fisher Scientific Inc., and Tosoh Corp. as some of the major market participants. The usage of myoglobin as a biomarker for the diagnosis of ACS and muscle will offer immense growth opportunities. To leverage the current opportunities, market vendors must strengthen their foothold in the fast-growing segments while maintaining their positions in the slow-growing segments. Request Sample Report Here Myoglobin Market 2022-2026: Segmentation Type Animal Myoglobin Human Myoglobin The market growth in the animal myoglobin segment will be significant over the forecast period. The segment is driven by the availability of a range of animal myoglobin products. Geography North America Europe Asia Rest Of World (ROW) North America will emerge as the major market, occupying 40% of the global market share. Factors such as the well-established biotechnology industry in the US and the growing investments in the research and development (R&D) of cardiac biomarkers drive the growth of the regional market. The report also covers the following areas: Myoglobin Market Size Myoglobin Market Trends Myoglobin Market Industry Analysis Myoglobin Market 2022-2026: Key Highlights CAGR of the market during the forecast period 2022-2026 Detailed information on factors that will assist myoglobin market growth during the next five years Estimation of the myoglobin market size and its contribution to the parent market Predictions on upcoming trends and changes in consumer behavior The growth of the myoglobin market Analysis of the market's competitive landscape and detailed information on vendors Comprehensive details of factors that will challenge the growth of myoglobin market vendors Related Reports: Recombinant Proteins Market by Application and Geography - Forecast and Analysis 2022-2026 Neurological Biomarkers Market by Indication, End-user, and Geography - Forecast and Analysis 2022-2026 Table of Contents: 1 Executive Summary 1.1 Market overview Exhibit 01: Executive Summary – Chart on Market Overview Exhibit 02: Executive Summary – Data Table on Market Overview Exhibit 03: Executive Summary – Chart on Global Market Characteristics Exhibit 04: Executive Summary – Chart on Market by Geography Exhibit 05: Executive Summary – Chart on Market Segmentation by Type Exhibit 06: Executive Summary – Chart on Incremental Growth Exhibit 07: Executive Summary – Data Table on Incremental Growth Exhibit 08: Executive Summary – Chart on Vendor Market Positioning 2 Market Landscape 2.1 Market ecosystem Exhibit 09: Parent market Exhibit 10: Market Characteristics 3 Market Sizing 3.1 Market definition Exhibit 11: Offerings of vendors included in the market definition 3.2 Market segment analysis Exhibit 12: Market segments 3.3 Market size 2021 3.4 Market outlook: Forecast for 2021-2026 Exhibit 13: Chart on Global - Market size and forecast 2021-2026 ($ million) Exhibit 14: Data Table on Global - Market size and forecast 2021-2026 ($ million) Exhibit 15: Chart on Global Market: Year-over-year growth 2021-2026 (%) Exhibit 16: Data Table on Global Market: Year-over-year growth 2021-2026 (%) 4 Five Forces Analysis 4.1 Five forces summary Exhibit 17: Five forces analysis - Comparison between 2021 and 2026 4.2 Bargaining power of buyers Exhibit 18: Chart on Bargaining power of buyers – Impact of key factors 2021 and 2026 4.3 Bargaining power of suppliers Exhibit 19: Bargaining power of suppliers – Impact of key factors in 2021 and 2026 4.4 Threat of new entrants Exhibit 20: Threat of new entrants – Impact of key factors in 2021 and 2026 4.5 Threat of substitutes Exhibit 21: Threat of substitutes – Impact of key factors in 2021 and 2026 4.6 Threat of rivalry Exhibit 22: Threat of rivalry – Impact of key factors in 2021 and 2026 4.7 Market condition Exhibit 23: Chart on Market condition - Five forces 2021 and 2026 5 Market Segmentation by Type 5.1 Market segments Exhibit 24: Chart on Type - Market share 2021-2026 (%) Exhibit 25: Data Table on Type - Market share 2021-2026 (%) 5.2 Comparison by Type Exhibit 26: Chart on Comparison by Type Exhibit 27: Data Table on Comparison by Type 5.3 Animal myoglobin - Market size and forecast 2021-2026 Exhibit 28: Chart on Animal myoglobin - Market size and forecast 2021-2026 ($ million) Exhibit 29: Data Table on Animal myoglobin - Market size and forecast 2021-2026 ($ million) Exhibit 30: Chart on Animal myoglobin - Year-over-year growth 2021-2026 (%) Exhibit 31: Data Table on Animal myoglobin - Year-over-year growth 2021-2026 (%) 5.4 Human myoglobin - Market size and forecast 2021-2026 Exhibit 32: Chart on Human myoglobin - Market size and forecast 2021-2026 ($ million) Exhibit 33: Data Table on Human myoglobin - Market size and forecast 2021-2026 ($ million) Exhibit 34: Chart on Human myoglobin - Year-over-year growth 2021-2026 (%) Exhibit 35: Data Table on Human myoglobin - Year-over-year growth 2021-2026 (%) 5.5 Market opportunity by Type Exhibit 36: Market opportunity by Type ($ million) 6 Customer Landscape 6.1 Customer landscape overview Exhibit 37: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria 7 Geographic Landscape 7.1 Geographic segmentation Exhibit 38: Chart on Market share by geography 2021-2026 (%) Exhibit 39: Data Table on Market share by geography 2021-2026 (%) 7.2 Geographic comparison Exhibit 40: Chart on Geographic comparison Exhibit 41: Data Table on Geographic comparison 7.3 North America - Market size and forecast 2021-2026 Exhibit 42: Chart on North America - Market size and forecast 2021-2026 ($ million) Exhibit 43: Data Table on North America - Market size and forecast 2021-2026 ($ million) Exhibit 44: Chart on North America - Year-over-year growth 2021-2026 (%) Exhibit 45: Data Table on North America - Year-over-year growth 2021-2026 (%) 7.4 Europe - Market size and forecast 2021-2026 Exhibit 46: Chart on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 47: Data Table on Europe - Market size and forecast 2021-2026 ($ million) Exhibit 48: Chart on Europe - Year-over-year growth 2021-2026 (%) Exhibit 49: Data Table on Europe - Year-over-year growth 2021-2026 (%) 7.5 Asia - Market size and forecast 2021-2026 Exhibit 50: Chart on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 51: Data Table on Asia - Market size and forecast 2021-2026 ($ million) Exhibit 52: Chart on Asia - Year-over-year growth 2021-2026 (%) Exhibit 53: Data Table on Asia - Year-over-year growth 2021-2026 (%) 7.6 Rest of World (ROW) - Market size and forecast 2021-2026 Exhibit 54: Chart on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 55: Data Table on Rest of World (ROW) - Market size and forecast 2021-2026 ($ million) Exhibit 56: Chart on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) Exhibit 57: Data Table on Rest of World (ROW) - Year-over-year growth 2021-2026 (%) 7.7 US - Market size and forecast 2021-2026 Exhibit 58: Chart on US - Market size and forecast 2021-2026 ($ million) Exhibit 59: Data Table on US - Market size and forecast 2021-2026 ($ million) Exhibit 60: Chart on US - Year-over-year growth 2021-2026 (%) Exhibit 61: Data Table on US - Year-over-year growth 2021-2026 (%) 7.8 China - Market size and forecast 2021-2026 Exhibit 62: Chart on China - Market size and forecast 2021-2026 ($ million) Exhibit 63: Data Table on China - Market size and forecast 2021-2026 ($ million) Exhibit 64: Chart on China - Year-over-year growth 2021-2026 (%) Exhibit 65: Data Table on China - Year-over-year growth 2021-2026 (%) 7.9 Germany - Market size and forecast 2021-2026 Exhibit 66: Chart on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 67: Data Table on Germany - Market size and forecast 2021-2026 ($ million) Exhibit 68: Chart on Germany - Year-over-year growth 2021-2026 (%) Exhibit 69: Data Table on Germany - Year-over-year growth 2021-2026 (%) 7.10 Canada - Market size and forecast 2021-2026 Exhibit 70: Chart on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 71: Data Table on Canada - Market size and forecast 2021-2026 ($ million) Exhibit 72: Chart on Canada - Year-over-year growth 2021-2026 (%) Exhibit 73: Data Table on Canada - Year-over-year growth 2021-2026 (%) 7.11 UK - Market size and forecast 2021-2026 Exhibit 74: Chart on UK - Market size and forecast 2021-2026 ($ million) Exhibit 75: Data Table on UK - Market size and forecast 2021-2026 ($ million) Exhibit 76: Chart on UK - Year-over-year growth 2021-2026 (%) Exhibit 77: Data Table on UK - Year-over-year growth 2021-2026 (%) 7.12 Market opportunity by geography Exhibit 78: Market opportunity by geography ($ million) 8 Drivers, Challenges, and Trends 8.1 Market drivers 8.2 Market challenges 8.3 Impact of drivers and challenges Exhibit 79: Impact of drivers and challenges in 2021 and 2026 8.4 Market trends 9 Vendor Landscape 9.1 Overview 9.2 Vendor landscape Exhibit 80: Overview on Criticality of inputs and Factors of differentiation 9.3 Landscape disruption Exhibit 81: Overview on factors of disruption 9.4 Industry risks Exhibit 82: Impact of key risks on business 10 Vendor Analysis 10.1 Vendors covered Exhibit 83: Vendors covered 10.2 Market positioning of vendors Exhibit 84: Matrix on vendor position and classification 10.3 Abbott Laboratories Exhibit 85: Abbott Laboratories - Overview Exhibit 86: Abbott Laboratories - Business segments Exhibit 87: Abbott Laboratories - Key news Exhibit 88: Abbott Laboratories - Key offerings Exhibit 89: Abbott Laboratories - Segment focus 10.4 Bio Rad Laboratories Inc. Exhibit 90: Bio Rad Laboratories Inc. - Overview Exhibit 91: Bio Rad Laboratories Inc. - Business segments Exhibit 92: Bio Rad Laboratories Inc. - Key news Exhibit 93: Bio Rad Laboratories Inc. - Key offerings Exhibit 94: Bio Rad Laboratories Inc. - Segment focus 10.5 F. Hoffmann La Roche Ltd. Exhibit 95: F. Hoffmann La Roche Ltd. - Overview Exhibit 96: F. Hoffmann La Roche Ltd. - Business segments Exhibit 97: F. Hoffmann La Roche Ltd. - Key news Exhibit 98: F. Hoffmann La Roche Ltd. - Key offerings Exhibit 99: F. Hoffmann La Roche Ltd. - Segment focus 10.6 Merck KGaA Exhibit 100: Merck KGaA - Overview Exhibit 101: Merck KGaA - Business segments Exhibit 102: Merck KGaA - Key news Exhibit 103: Merck KGaA - Key offerings Exhibit 104: Merck KGaA - Segment focus 10.7 OriGene Technologies Inc. Exhibit 105: OriGene Technologies Inc. - Overview Exhibit 106: OriGene Technologies Inc. - Product / Service Exhibit 107: OriGene Technologies Inc. - Key offerings 10.8 PerkinElmer Inc. Exhibit 108: PerkinElmer Inc. - Overview Exhibit 109: PerkinElmer Inc. - Business segments Exhibit 110: PerkinElmer Inc. - Key news Exhibit 111: PerkinElmer Inc. - Key offerings Exhibit 112: PerkinElmer Inc. - Segment focus 10.9 Randox Laboratories Ltd. Exhibit 113: Randox Laboratories Ltd. - Overview Exhibit 114: Randox Laboratories Ltd. - Product / Service Exhibit 115: Randox Laboratories Ltd. - Key offerings 10.10 Scripps Laboratories Inc. Exhibit 116: Scripps Laboratories Inc. - Overview Exhibit 117: Scripps Laboratories Inc. - Product / Service Exhibit 118: Scripps Laboratories Inc. - Key offerings 10.11 Thermo Fisher Scientific Inc. Exhibit 119: Thermo Fisher Scientific Inc. - Overview Exhibit 120: Thermo Fisher Scientific Inc. - Business segments Exhibit 121: Thermo Fisher Scientific Inc. - Key news Exhibit 122: Thermo Fisher Scientific Inc. - Key offerings Exhibit 123: Thermo Fisher Scientific Inc. - Segment focus 10.12 Tosoh Corp. Exhibit 124: Tosoh Corp. - Overview Exhibit 125: Tosoh Corp. - Business segments Exhibit 126: Tosoh Corp. - Key offerings Exhibit 127: Tosoh Corp. - Segment focus 11 Appendix 11.1 Scope of the report 11.2 Inclusions and exclusions checklist Exhibit 128: Inclusions checklist Exhibit 129: Exclusions checklist 11.3 Currency conversion rates for US$ Exhibit 130: Currency conversion rates for US$ 11.4 Research methodology Exhibit 131: Research methodology Exhibit 132: Validation techniques employed for market sizing Exhibit 133: Information sources 11.5 List of abbreviations Exhibit 134: List of abbreviations About Us Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: [email protected] Website: SOURCE Technavio

14 May 2021

·www.globenewswire.com

Worldwide Hemoglobin Testing Industry to 2026 - Players Include Abbott, Bio-Rad Laboratories and Danaher Among Others

Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Hemoglobin Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The global hemoglobin testing market exhibited moderate growth during 2015-2020. A hemoglobin test measures the count of red blood cells (RBC) or the level of hemoglobin in the blood. Hemoglobin is a type of protein present in the RBCs that carries oxygen to the organs and transports carbon dioxide back to the lungs. Hemoglobin tests are used extensively by doctors as a part of their routine check-ups or to diagnose a serious medical condition in the patient. If a test reveals that the hemoglobin level in an individual's body is lower than normal, it means that they have a low RBC count and are prone to disorders such as anemia. If the RBC count is higher than normal, it could be an indication for a blood disorder or can be caused by living at a high altitude, smoking and dehydration. The key end users of hemoglobin testing market are medical laboratories, hospitals and research centers.An increasing prevalence of chronic disorders such as anemia and diabetes represent a key factor driving the global hemoglobulin testing market. In 2018, an estimated 490 Million people around the world suffered from diabetes. The prevalence of diabetes is currently being catalysed by an increasing ageing population, poor dietary habits, sedentary lifestyles and rising levels of obesity. Patients suffering from diabetes need to undergo tests to measure blood glucose and HbA1c levels regularly, driving the demand for such tests. Moreover, factors such as favourable reimbursement of hemoglobin testing under various health insurance policies is also catalyzing the growth of the market. However, in many countries, medical insurance doesn't fully reimburse the cost of hemoglobin testing, but with partial payment and other coverages, consumers are increasingly adopting regular and periodic tests in order to check and maintain their overall health. Furthermore, factors such as improving health infrastructure, increasing per capita expenditure on health care, rising awareness for blood-related ailments, ageing population, technological advancements, etc. are also projected to drive the global hemoglobin testing market in the coming years. Looking forward, the publisher expects the global hemoglobin testing market to grow at a CAGR of 6.80% during 2021-2026.Report Coverage: Market Breakup by Product Type: Market Breakup by Technology: Market Breakup by End-User: Market Breakup by Region: Competitive Landscape: The report has also analysed the competitive landscape of the market with some of the key players being Abbott, Bio-Rad Laboratories, Danaher, EKF Diagnostics, F. Hoffmann-La Roche, Siemens Healthineers, Thermo Fisher Scientific, Alere, ACON Laboratories, ARKRAY, Bayer Medical Care, Daiichi Biotech, DiaSys Diagnostic Systems, Epinex Diagnostics, Erba Diagnostics, etc Key Questions Answered in This Report: Key Topics Covered: 1 Preface2 Scope and Methodology3 Executive Summary4 Introduction4.1 Overview4.2 Key Industry Trends5 Global Hemoglobin Testing Market5.1 Market Overview5.2 Market Performance5.3 Impact of COVID-195.4 Market Breakup by Product Type5.5 Market Breakup by Technology5.6 Market Breakup by End-User5.7 Market Breakup by Region5.8 Market Forecast6 Market Breakup by Product Type6.1 Reagents and Consumables6.1.1 Market Trends6.1.2 Market Forecast6.2 Equipment6.2.1 Market Trends6.2.2 Market Forecast7 Market Breakup by Technology7.1 Chromatography7.1.1 Market Trends7.1.2 Market Forecast7.2 Immunoassay7.2.1 Market Trends7.2.2 Market Forecast7.3 Others7.3.1 Market Trends7.3.2 Market Forecast8 Market Breakup by End-User8.1 Laboratories8.1.1 Market Trends8.1.2 Market Forecast8.2 Hospitals8.2.1 Market Trends8.2.2 Market Forecast8.3 Research centers8.3.1 Market Trends8.3.2 Market Forecast9 Market Breakup by Region9.1 Europe9.1.1 Market Trends9.1.2 Market Forecast9.2 North America9.2.1 Market Trends9.2.2 Market Forecast9.3 Asia Pacific9.3.1 Market Trends9.3.2 Market Forecast9.4 Middle East and Africa9.4.1 Market Trends9.4.2 Market Forecast9.5 Latin America9.5.1 Market Trends9.5.2 Market Forecast10 SWOT Analysis10.1 Overview10.2 Strengths10.3 Weaknesses10.4 Opportunities10.5 Threats11 Value Chain Analysis12 Porters Five Forces Analysis12.1 Overview12.2 Bargaining Power of Buyers12.3 Bargaining Power of Suppliers12.4 Degree of Competition12.5 Threat of New Entrants12.6 Threat of Substitutes13 Price Analysis14 Competitive Landscape14.1 Market Structure14.2 Key Players14.3 Profiles of Key Players14.3.1 Abbott14.3.2 Bio-Rad Laboratories14.3.3 Danaher14.3.4 EKF Diagnostics14.3.5 F. Hoffmann-La Roche14.3.6 Siemens Healthineers14.3.7 Thermo Fisher Scientific14.3.8 Alere14.3.9 ACON Laboratories14.3.10 ARKRAY 14.3.11 Bayer Medical Care 14.3.12 Daiichi Biotech 14.3.13 DiaSys Diagnostic Systems 14.3.14 Epinex Diagnostics 14.3.15 Erba Diagnostics For more information about this report visit

100 Deals associated with DiaSys Diagnostic Systems GmbH

100 Translational Medicine associated with DiaSys Diagnostic Systems GmbH

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 23 Nov 2024

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis